CELL CULTURE PROCESS
A cell culture medium comprising tyrosine at a concentration of at least 3 mM and polyvinylalcohol (PVA).
1 . A cell culture medium comprising tyrosine at a concentration of at least 4 mM and polyvinylalcohol (PVA).
2 . (canceled)
3 . The cell culture medium according to claim 1 wherein the concentration of tyrosine is at least 10 mM.
4 . The cell culture medium according to claim 1 wherein the concentration of tyrosine is between 5 and 20 mM.
5 . The cell culture medium according to claim 1 wherein the concentration of PVA is at least 0.5 g/L.
6 . The cell culture medium according to claim 1 wherein the concentration of PVA is between 0.5 and 5 g/L.
7 . (canceled)
8 . (canceled)
9 . The cell culture medium according to claim 1 wherein said medium is protein free.
10 . The cell culture medium according to claim 1 wherein the turbidity is less than 5NTU after two weeks storage at 4° C. in the absence of light.
11 . (canceled)
12 . The cell culture medium according to claim 1 wherein the medium comprises 4 to 10 mM Ala, 30 to 60 mM Arg, 50 to 90 mM Asn, 10 to 30 mM Asp, 2 to 40 mM Glu, 2 to 15 mM Gly, 8 to 20 mM His, 25 to 32 mM Ile, 35 to 60 mM Leu, 28 to 60 mM Lys, 9 to 25 mM Met, 10 to 30 mM Phe, 15 to 40 mM Pro, 44 to 80 mM Ser, 20 to 45 mM Thr, 2 to 10 mM Trp and 20 to 50 mM Val.
13 . A method of cell culture comprising contacting mammalian cells with a cell culture medium according to claim 1 .
14 . (canceled)
15 . The method of claim 13 , wherein the mammalian cells are CHO cells.
16 . (canceled)
17 . The method of claim 13 , wherein the cell culture is a fed batch culture.
18 . The method of claim 17 , wherein the fed batch culture comprises a base medium supplemented with feed media.
19 . The method of claim 18 , wherein only the base medium is a medium according to claim 1 .
20 . The method of claim 18 wherein only the feed medium is a medium according to claim 1 .
21 . The method of claim 18 , wherein the base medium and the feed medium are media according to claim 1 .
22 . The method of claim 13 wherein the maximum viable cell density during the cell culture is above 1×10 6 cells/mL.
23 . The method of claim 22 wherein the maximum viable cell density is above 5×10 6 cells/mL, 1×10 7 cells/mL, 5×10 7 cells/mL, 1×10 8 cells/mL or 5×10 8 cells/mL.
24 . The method of claim 13 wherein the volume of the cell culture medium is at least 500 L.
25 . The method of claim 24 , wherein the volume of the cell culture medium is at least 5000 L.
26 . The method of claim 13 , wherein the cells express a recombinant protein.
27 . The method of claim 26 , wherein the recombinant protein is selected from the group consisting of antibodies or fragments thereof, nanobodies, single domain antibodies, Small Modular ImmunoPharmaceuticals™ (SMIPs), VHH antibodies, camelid antibodies, shark single domain polypeptides (IgNAR), single domain scaffolds (e.g., fibronectin scaffolds), SCORPION™ therapeutics (single chain polypeptides comprising an N-terminal binding domain, an effector domain, and a C-terminal binding domain), growth factors, clotting factors, cytokines, fusion proteins, pharmaceutical drug substances, vaccines, enzymes and combinations thereof.
28 . The method of claim 26 , further comprising obtaining recombinant protein produced by the cells.
29 . The method of claim 28 , further comprising purifying the recombinant protein.
30 . A pharmaceutical composition comprising a purified recombinant protein obtained by the method according to claim 29 in combination with a pharmaceutically acceptable carrier.